The Role of the Microbiome in Gastrointestinal Inflammation

David J. Sanders¹, Saskia Inniss¹, Gregory Sebepos-Rogers¹, Farooq Z. Rahman², Andrew M. Smith¹*

¹ Department of Microbial Diseases, UCL Eastman Dental Institute, Royal Free Campus, University College London, London, United Kingdom.

² Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London NW1 2PG, United Kingdom.

*To whom correspondence should be addressed.
Email: andrew.m.smith@ucl.ac.uk
Abstract

The microbiome plays an important role in maintaining human health. Despite multiple factors being attributed to the shaping of the human microbiome, extrinsic factors such as diet and use of medications including antibiotics appear to dominate. Mucosal surfaces, particularly in the gut, are highly adapted to be able to tolerate a large population of microorganisms while still being able to produce a rapid and effective immune response against infection. The intestinal microbiome is not functionally independent from the host mucosa and can, through presentation of microbe-associated molecular patterns and generation of microbial-derived metabolites, fundamentally influence mucosal barrier integrity and modulate host immunity. In a healthy gut there is an abundance of beneficial bacteria that help to preserve intestinal homeostasis, promote protective immune responses and limit excessive inflammation. The importance of the microbiome is further highlighted during dysbiosis where a loss of this finely-balanced microbial population can lead to mucosal barrier dysfunction, aberrant immune responses, and chronic inflammation that increases the risk of disease development. Improvements in our understanding of the microbiome are providing opportunities to harness members of a healthy microbiome to help reverse dysbiosis, reduced inflammation and ultimately prevent disease progression.
Introduction

The human body is inhabited by a highly diverse population of microorganisms (microbiota) that has co-evolved with their human hosts over many millennia (1). The human microbiome, a term more precisely used to describe the genomes of these microorganisms (2), is predominantly made up of bacteria (3), however archaea, viruses, and single-cell eukaryotes (e.g. fungi and protists) are also present (4-7). These microorganisms are at least as abundant as the number of human host cells (3, 8) and combined contain far more genes than the entire human genome (9). Over the past few decades, research related to the microbiome has intensified, facilitated by rapid advances in culture-independent, high-throughput genomic and metabolomic techniques (10-12). Consequently, a greater understanding of microbiota population composition and host-microbe interactions has been achieved, especially in the context of human health and disease (11, 13, 14). Whereas a balanced microbiota has been shown to play an important role in the maintenance of human health, impairment or imbalance in the makeup of the human microbiota (dysbiosis) can disrupt homeostasis and lead to the onset or exacerbation of human disease (15). Multiple factors are known to influence the microbiota however studies have shown that the microbiome is more strongly influenced by an individual’s environment (16, 17). There are significant similarities in microbiota composition of genetically unrelated individuals who share a household, with approximately 20% of inter-person microbiota variability associated with environmental factors such as diet, lifestyle, and medication (16).

The human microbiome can be separated into compartment-specific ecosystems that exist on the skin and along mucosal surfaces such as those of the oral cavity, gastrointestinal tract, lungs, and genitourinary system (1). The largest concentration and diversity of microbiota can be found within the gut especially in the colon (1). The mucosa, which consists of a single cell thick epithelium overlaying a layer of connective tissue called the lamina propria, provides the interface between the host and the environment and is equipped with specialised features, particularly along its apical surface, to allow physiological function while also being in contact with the microbiota (18). The microbiota is however not functionally independent from the host mucosa and can fundamentally influence mucosal integrity, modulating host immune responses and mucosal inflammation.

Here we review the relationship between the microbiota and the mucosa, especially in relation to gut homeostasis and mucosal inflammation. We first discuss factors that shape an individual’s microbiome and the impact the microbiome has on the intestinal mucosa during homeostasis. We then explore how dysbiosis of the microbiome can lead to mucosal inflammation, resulting in the development of human disease, and highlight current and emerging therapies being used to suppress mucosal inflammation through targeting of the microbiome.
1. Factors Shaping the Microbiome

There is increasing evidence to suggest that there is a core microbiome shared between all individuals (19). However, the composition and diversity of much of the gut microbiome varies greatly from person to person, adapting to both intrinsic and environmental factors (20, 21). Research to date has shown that environmental factors, mainly diet and medication, dominate over intrinsic factors, such as host genetics, in shaping the microbiome (16, 22). Age (23, 24), geography (25), and birthing practices (26, 27) are also known to be particularly important for determining microbiome composition (Figure 1).

![Diet](image1)

**Figure 1. Factors that contribute to the shaping of the human microbiome.**

1.1 Diet

In the first year of life the gut microbiome is relatively unstable becoming progressively more stable following weaning, taking on an adult form typically around three years of age (28). Infant feeding practices as well as adult habitual diet play an important role in shaping the gut microbiome (29). Studies looking into the effect of diet on the make-up of the intestinal microbiota have to date mainly focused on the so-called ‘Western’ diet, which is characterised by high levels of fat, sugar and refined protein (30, 31), and diets that are high in fibre and low in red meat, such as the Mediterranean diet (24, 32).

Differences in gut microbiome composition prior to weaning have been observed between breastfed and formula-fed infants. Breastfed infants have a microbiome dominated by Lactobacilli and Prevotella, whereas formula-fed infants exhibit a more diverse microbial population, dominated by Enterococci, Enterobacteria, Bacteroides, Clostridia and Streptococci (33, 34). Breastmilk contains oligosaccharides which promote the growth of beneficial Bifidobacteria (35). Bifidobacteria play a major role in the fermentation and conversion of oligosaccharides into short-chain fatty acids (SCFA), such as butyrate and propionate, which promote healthy immune function (reviewed in detail in Section 2.1) (36).

In addition to providing critical nutrients and bioactive compounds, human breast milk also plays an important role in the seeding of an infant’s gut microbiome, containing a variety of beneficial bacteria, including Lactobacilli and Bifidobacteria (37). After weaning, the microbiota becomes more diverse and is dominated by Bacteroidetes and Firmicutes (38).
Studies looking at the adult gut microbiome have found that individuals consuming a Western diet experience a decrease in the total number of gut bacteria, particularly Bifidobacteria and Eubacteria, and an increase in pro-inflammatory bacterial-derived compounds (39-41). A key aspect of the Western diet is a high intake of saturated fatty acids which has been linked to both a decrease in Gram-negative bacteria within the gut, particularly Bacteroidetes, and an increase in Lactococci (42, 43). Whilst there is currently a lack of consensus as to the precise effect of these dietary components on the microbiome, most studies have observed an overall decrease in bacterial diversity, a decrease in SCFA production, and an increase in harmful bacterial strains, such as pathogenic Escherichia coli (E. coli) (44, 45). In contrast to a Western diet, adults who consume a Mediterranean diet exhibit increased levels of Bifidobacteria, Lactobacilli, Eubacteria and Bacteroides (46, 47). Furthermore, individuals who consume a Mediterranean diet have been shown to have increased levels of SCFA-producing bacteria, such as Provetella (48). In addition to habitual diet, research has shown that dietary diversity, meal timing as well as short- and long-term dietary modifications can change the composition and activity of the adult gut microbiome (49-52). Caloric restriction, for example, which is a nutritional intervention of reduced energy intake, has a strong influence on the gut microbiota (53, 54). It has been found that caloric restriction can slow down age-related decline in the microbiome, increase both microbial diversity and Bacteroidetes/Firmicutes ratio, as well as change host microbial co-metabolites leading to a decrease in host lipid biosynthesis and an increase in fatty acid catabolism (55, 56).

1.2 Antibiotics and Drugs

Antibiotics are medicines used in the treatment of bacterial infections. Whilst they have proved to be an effective treatment against many bacterial diseases, their antimicrobial action profoundly affects the composition and function of the gut microbiome, causing dysbiosis by killing both pathologic and beneficial bacteria, and allowing the expansion of resistant microbes (57). The effects of antibiotics on the gut microbiome are potentially long-lasting, and their use in early life has been associated with an increased risk of developing several conditions including inflammatory bowel disease (IBD) and asthma (58, 59).

Antibiotics can drastically reduce, or even fully eliminate, beneficial anaerobic bacterial species such as Bifidobacteria, Lactobacilli, Bacteroides and Clostridia (60). After only 7 days of antibiotic treatment, microbial diversity has been found to decrease by 25%, with core phylogenetic microbiota reducing from 29 to 12 taxa and antibiotic resistant Bacteroidetes increasing 2.5-fold (61). Consequently, antibiotic use can also result in reduced SCFA production (62). The effects of antibiotics on the microbiome are however dependent on the type of antibiotic used. Clindamycin, which is a broad-spectrum antibiotic, can cause microbial changes that last for up to 2 years with no recovery in Bacteroides diversity (63). Clarithromycin and Ciprofloxacin, which are used against Helicobacter pylori, are associated with a decrease in Actinobacteria and Ruminococci, respectively (64, 65). Vancomycin, which is used to treat Clostridium difficile (C. difficile), causes an increase in Proteobacteria species and a decrease in Bacteroidetes, Ruminococci and Faecalibacteria levels, which can lead to both recurrent C. difficile infection and the growth of unwanted bacterial species, such as pathogenic E. coli (66, 67).

Non-antibiotic drugs are also known to influence the composition and stability of the microbiome. A recent meta-analysis revealed that in addition to antibiotics, proton pump inhibitors (PPIs), metformin, and laxatives exhibit the greatest effects on gut microbiome composition and function (68). Proton pump inhibitors reduce microbial diversity and cause taxonomical changes in the gut. Metformin significantly increases E. coli abundance and effects the number of SCFA producing bacteria (68, 69).

1.3 Birth Mode of Delivery

Studies have shown that whereas vaginally delivered babies have a microbiome dominated by Lactobacilli and Prevotella, babies born by caesarean section (C-section) carry a microbiome dominated by Streptococci, Corynebacteria, and Propionibacteria (70, 71). Furthermore, babies born by C-section have been shown to have an abundance of potentially pro-inflammatory Klebsiella and Enterococcus bacteria (26). A recent study reported that the abundance of Klebsiella and Enterococcus species in C-section born children at one week of life was associated with an increased number of respiratory infections over the first year (26). Additionally, babies delivered by C-section have been shown to have...
lower total gut microbial diversity, delayed Bacteroidetes colonisation, and a subsequent immune system imbalance during the first two years of life which may result in the development of allergies (72, 73).

1.4 Age

Many studies have observed age-related changes to the gut microbiome. In infancy, the developing gut microbiome undergoes three distinct phases of progression: a developmental phase (months 3-14), a transitional phase (months 15-30), and a stable phase (months 31-46) (74). Children and young adults have a higher abundance of Bifidobacteria and Clostridia, and a lower microbial diversity compared to adults (75). In general, healthy adults exhibit high levels of Bacteroidetes and Firmicutes, and low levels of Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia (20, 76, 77). Throughout life, intestinal levels of Firmicutes decrease while Bacteroidetes levels increase. Elderly people have a gut microbiome enriched with Bacteroidetes and Proteobacteria and depleted levels of Bifidobacteria and Lactobacilli (24, 78). The transition from healthy adult to healthy old age is characterised by a decrease in microbial diversity, as well as an accumulation of potentially pro-inflammatory microbes and decrease of beneficial microbes (79).

1.5 Development Geography

To date, most studies investigating the link between the microbiome and geography have focused on differences in microbiome composition between three contrasting human populations: hunter gatherers, traditional farming or fishing communities, and Western industrialised communities (80-84). When comparing the microbiomes of hunter gatherers to those of more developed communities, hunter gatherers were found to have a higher microbial diversity, with enrichment of Prevotella, Treponema and Bacteroidetes (80, 81). In contrast, Western industrialised communities have higher levels of Bacteroidetes and Firmicutes, with an overall lower microbial diversity. Some studies suggest that the microbiomes of traditional farming and fishing communities exhibit an intermediate state between hunter gatherers and Western industrialised communities (82, 85). Factors thought to influence gut microbiome composition amongst hunter gatherers include a diet consisting of predominantly starchy foods, limited access to modern medicine, and exposure to a wide variety of pathogens and parasites (82, 83). Traditional farming or fishing communities are thought to possess microbiomes with a relatively high taxonomic diversity, allowing the host to withstand pathogens and parasites, as well as to be able to respond to dietary fluctuations due to crop seasonality (83). In Western industrialised societies, the gut microbiome is thought to be largely determined by diets high in refined protein and fat, good sanitation and hygiene practices, and the habitual use of antibiotics and other medications (80, 81, 84). Some studies have also proposed that the lower microbiome diversity found in Western industrialised communities can be attributed to an overall loss of biodiversity due to industrialisation, pollution and use of chemicals (86, 87). Furthermore, differences in sanitised drinking water may also have an effect on the composition of the gut microbiome (88, 89).

2. The microbiome and intestinal homeostasis

The intestinal mucosa is highly adapted to be able to tolerate a large population of microorganisms and dietary antigens while preserving nutrient uptake and raising an effective immune response to pathogenic infection or commensal intrusion into the underlying host tissue (90). For the most part, the microbiota maintains symbiosis with the gut environment forming a mutually beneficial relationship with the host. The gut provides a nutrient-rich habitat for the microbiota while the microbiota stimulates the host’s immune system, aids digestion, and provides otherwise unobtainable metabolites. In a normal healthy gut, the microbiota is diverse with an abundance of beneficial bacteria that help to maintain gut homeostasis, promoting protective intestinal immune responses at the mucosal surface and limiting excessive mucosal inflammation (91).

The microbiota can communicate directly with the host through host recognition of highly conserved structural components, termed microbe-associated molecular patterns (MAMPs) (92), such as lipopolysaccharides (LPS), peptidoglycan (PGN), and flagellin. Recognition of MAMPs are achieved
primarily through binding to pattern-recognition receptors (PRRs) expressed by intestinal epithelial cells (IECs) and immune cells. PPRs are a diverse family of transmembrane and cytoplasmic innate immune receptors, that include Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) (93). PPR stimulation triggers intracellular signalling cascades leading to the expression of a range of immunomodulatory molecules that orchestrate early immune responses resulting in mucosal inflammation and further activation of innate and adaptive immune processes (94). Whereas activation of PRR by pathogens and pathobionts is known to initiate pro-inflammatory signalling cascades that lead to mucosal inflammation, the commensal microbiota can use similar mechanisms to dampen inflammation and promote intestinal homeostasis (95). For example, polysaccharide A (PSA) from the ubiquitous gut commensal Bacteroides fragilis is recognised by the TLR1/TLR2 heterodimer, in co-operation with the C-type lectin PRR Dectin-1, triggering a signalling cascade through the phosphoinositide 3-kinase (PI3K) pathway to promote 3',5'-cyclic adenosine monophosphate (cAMP) response-element-binding protein (CREB)-dependent transcription of anti-inflammatory genes (96). NOD2 stimulation by muramyl dipeptide (MDP), a PGN motif, triggers intestinal leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5)\textsuperscript{\textdagger} stem cell survival and epithelial regeneration (97). In addition to microbe specific constituents, there are also numerous microbiota-derived metabolites, such as SCFA, that stimulate a range of signalling pathways to further regulate mucosal immune responses and aid microbial symbiosis/tolerance (98).

### 2.1 Direct microbial maintenance of intestinal barrier integrity

The intestinal mucosa forms physical, biochemical, and immunological barriers which allows for the symbiotic microbiota-host relationship to be maintained, controlling the microbial population and reducing direct contact with the host (99). Maintenance of these barriers is essential for preventing microbial invasion, excessive immune responses, and mucosal inflammation. As well as defending against pathogens through competition for nutrients and production of anti-microbial molecules (100, 101), the gut microbiota also plays an active role in the maintenance of host mucosal barriers, which further prevents colonisation by opportunistic pathogens, limiting excessive mucosal inflammation and preserving gut homeostasis (99, 100).

The physical barrier consists of a wall of IECs that are held together by cell junctions, particularly tight junctions (TJs), allowing only selective paracellular transport of water, ions, solutes, and some nutrients, preventing passage of microorganisms (102). A mucus layer, predominantly formed of highly glycosylated mucins secreted by goblet cells, covers IECs and further contributes to the physical barrier preventing bacteria from interacting directly with host tissue (103). The mucus layer also provides moisture and lubrication to protect IECs from dehydration and mechanical stress caused by the passage of food and peristaltic forces (104). The small intestine contains one layer of mucus whereas the colon contains two: a loose outer layer that is permeable to bacteria and a dense inner layer that is impermeable and devoid of bacteria (105). In the small intestine particularly, secretory molecules such anti-microbial peptides (AMPs) and immunoglobulin (Ig)A are released and concentrated in the mucus layer, which further aid separation of the microbiota from the host mucosa (101, 106). In addition to targeting microbes directly and sequestering key nutrients to control microbiota biodiversity, these barriers can also modulate the host’s innate and adaptive immune responses (107, 108) and drive upregulation of mucin and TJ protein expression in IECs to maintain intestinal barrier integrity (109, 110).

Normal maturation and function of the mucus layer is strongly influenced by the gut microbiota, either through bacterial degradation and turn-over of mucin glycans or by bacteria-mediated processes to regulate host glycosylation of mucins (111). Additionally, microbial-derived signals and metabolites have been shown to protect the intestinal epithelial barrier, upregulating and strengthening cell junctions as well as promoting maintenance of the mucus layer and release of anti-microbial molecules (Figure 2). For example, indoles, which are microbiota-derived metabolites produced from the amino acid tryptophan have been shown to increase gene expression linked to TJ formation and mucus production (112, 113). Indoles further protect IECs through attenuation of tumour necrosis factor-alpha (TNF-\textalpha)-mediated activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\textkappaB), decreased expression of pro-inflammatory cytokine interleukin (IL)-8, reduced attachment of pathogenic E. coli, and increased expression of anti-inflammatory IL-10 (112). Studies using mice have shown that indole 3-propionic acid (IPA) stimulates the pregnane X receptor (PXR) resulting in upregulation of TJ proteins in enterocytes and down-regulation of TNF-\textalpha (114). Urolithin A (UroA), a solely microbiota-derived
metabolite produced from polyphenolic compounds also enhances intestinal barrier integrity by increasing TJ proteins in IECs through activation of the aryl hydrocarbon receptor (AhR)-nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent pathways (115). SCFAs, in particular butyrate, are the main energy source for colonocytes and are known to promote epithelial barrier integrity (116-119). SCFAs are taken up by cells either by passive diffusion or facilitated by solute transporters such as monocarboxylate-transporter 1 (MCT-1) and sodium-coupled monocarboxylate transporter 1 (SMCT1) where they can then be detected by intracellular receptors such as peroxisome proliferator-activated receptor gamma (PPARγ) (120-122). Alternatively, SCFAs may signal through G-protein coupled receptors (GPRs), such as GPR41, GPR43, and GPR109A, to activate signalling cascades that regulate immune responses (123-125). SCFAs directly promote mucosal barrier integrity through induction of genes encoding TJ proteins (126), mucins (127), and AMPs (128). The gut microbial-derived metabolite of polyunsaturated omega-6 fatty acid linoleic acid, 10-hydroxy-cis-12-octadecenoic acid (HYA), is able to ameliorate intestinal barrier damage and changes to cell junction proteins partially via a GPR40-mitogen activated protein kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway (129). Secondary bile acids, such as lithocholic acid (48), produced by gut microbial conversion of primary bile acids, have also been shown to protect IECs from a TNF-α-induced decrease in TJ proteins through activation of the vitamin D receptor (VDR)(130).

Figure 2. The direct effect of microbiota-derived metabolites on intestinal barrier integrity. Microbiota-derived metabolites play an important role in maintaining intestinal barrier integrity to prevent epithelial damage and limit mucosal inflammation. Metabolites of polyunsaturated fatty acids (PUFAs) via a GPR40-MEK-ERK pathway have been shown to prevent loss of TJ proteins. Indoles, SCFAs, UroA, and secondary bile acids have also been shown to increase expression of TJ proteins via pathways involving PXR, adenosine monophosphate activated protein kinase (AMPK), AhR-Nrf2, and VDR, respectively. Indoles and SCFAs promote the production and secretion of mucin, reinforcing the mucus layer. SCFAs activate a mechanistic target of rapamycin (mTOR)-signal transducer and activator of transcription (STAT) 3 pathway in a GPR43-dependent manner to induce production of AMPs.

2.2 Mucosal immune regulation by the microbiota

The mucosal immune system is fundamental to intestinal barrier integrity and inflammation. The microbiota plays a vital role, especially in early life, in the maturation and regulation of host immunity to ensure mucosal inflammation is controlled and that the host can differentiate between commensal and pathogenic bacteria (131).

Commensal bacteria have long been associated with the correct development of mucosa-associated lymphoid tissues (MALT), in particular the gut-associated lymphoid tissue (GALT) which includes Peyer’s patches. Early studies using germ-free (GF) mice have shown that the absence of a
commensal microbiota correlates with extensive defects in lymphoid tissue architecture and immune responses (132). A significant reduction in intra epithelial lymphocytes (IELs), such as αβ and γδ IELs, as well as secretory IgA, is seen in GF mice (compared to their colonised counterparts), which can be reversed following microbial colonisation (133, 134). Gestational maternal colonisation in mice has been shown to increase immune cell subtypes including intestinal group 3 innate lymphoid cells (ILC3s) and F4/80+ CD11c+ mononuclear cells (135). Pro-inflammatory IL-17+ CD4+ T helper (Th17) cells, which normally exist in large numbers in the lamina propria of the small intestine are absent in GF mice however they can be induced upon commensal colonisation (136-138). This is most notable with segmented filamentous bacteria (SFB), which upon adhesion to IECs, are known to stimulate T-cell responses as well as enhance IgA production (126, 139). PSA from *B. fragilis* aids cellular and physical maturation of the developing immune system in mice, correcting T-cell deficiencies and imbalances in CD4+ T helper 1 (Th1) and Th2 cell subtypes, directing lymphoid organogenesis (140). In neonatal mice, *B. fragilis* is also known to supplement the endogenous lipid antigen milieu with inhibitory sphingolipids, impeding invariant natural killer T (iNKT) cell proliferation in the colonic lamina propria, providing protection against iNKT cell-mediated mucosal inflammation and injury (141). Microbial colonisation also influences the development of early B-cell lineages in the intestinal mucosa, modulating gut immunoglobulin repertoires (142). Sufficient intestinal microbiota diversity during early life colonisation has been shown to be essential for the establishment of an immunoregulatory network that protects against elevated induction of IgE at mucosal sites, which is linked to immune hypersensitivity, mucosal inflammation, and allergies (72).

Beyond infancy, the gut microbiota continues to influence the host immune system to maintain host-microbiota symbiosis and intestinal homeostasis (Figure 3). For example, MAMPs and microbiota-derived metabolites can signal through activation of NLR complexes, called inflammasomes, to shape host immune responses and regulate mucosal barrier function. The microbiota induces NOD-, Leucine rich repeat (LRR)-, and pyrin domain containing 6 (NLRP6) inflammasome signalling to promote steady-state pro-inflammatory IL-18 mucosal secretion, which in turn activates AMP and mucin production in the intestinal mucosa, refining microbiota composition (143). SCFAs signal through GPR43 and GPR109A also activate NLRP3 leading to IL-18 mucosal secretion (124). Members of the microbiota, specifically *Proteus mirabilis*, can induce robust IL-1β production via the NLRP3 inflammasome to promote intestinal mucosal inflammation, mediated by monocytes that are recruited to the intestine in response to epithelial injury (144). The sensing of PGN fragments and PGN from intact commensal bacteria through multiple PPRs is necessary for the proper development and activation of immune cells. Phagocytes sense internalised PGNs through NLRs and inflammasome complexes (e.g. NLRP3) which induce secretion of pro-inflammatory cytokines (e.g. TNF-α, IL-6, IL-1β, and IL-18) as well as increase antimicrobial responses, such as reactive oxygen species (ROS) and AMP production (145). Macrophages play a vital role as innate immune effector cells to maintain intestinal homeostasis, being able to initiate both pro-inflammatory and anti-inflammatory signalling pathways. In mice, intestinal microbial colonisation has been shown to drive continuous replenishment of macrophages in the intestinal mucosa by monocytes that express C-C chemokine receptor type 2 (CCR2) (146). *Helicobacter hepaticus* induce an early IL-10 response in intestinal lamina propria-resident macrophages and produce a large soluble polysaccharide (LSP) that activates a specific mitogen and stress-activated protein kinase (MSK)/CREB-dependent anti-inflammatory signalling cascade via TLR2, aiding tolerance and mutualism (147). Butyrate drives monocyte to macrophage differentiation through histone deacetylase 3 (HDAC3) inhibition to promote an anti-microbial state without inducing pro-inflammatory cytokine production (148). Trimethylamine N-oxide (TMAO), the oxidated product of gut microbiota-derived trimethylamine, triggers M1 macrophage polarisation via NLRP3 inflammasome activation in mice resulting in Th1 and Th17 differentiation (149). Furthermore, TMAO has been shown to prime the NLRP3 inflammasome and increase generation of ROS via inhibition of autophagy in colonic epithelial cells contributing to mucosal inflammation (150).

Innate lymphoid cells (ILCs) are a heterogenous innate cell population that specialise in rapid secretion of polarising cytokines and are involved in the initiation of mucosal inflammation to fight infection and inflammatory resolution for mucosal tissue repair (151, 152). Many of the functions of ILCs are mediated by the microbiota (152, 153). For example, proliferation and function of colonic ILC3s is regulated by SCFA activation of GPR43. GPR43 agonism differentially activates protein kinase B (AKT) and ERK signalling, leading to increased colonic ILC3-derived IL-22, ensuring correct mucosal mucin
and AMP production from IECs (154, 155). Dichotomous regulation of ILCs has been observed by a pair of Helicobacter species, activating ILCs but negatively regulating proliferation of ILC3s (156).

PSA mediates the conversion of CD4+ cells into anti-inflammatory forkhead box P3 (Foxp3)+ regulatory T (Treg) cells and subsequent production of IL-10, both via TLR2, to suppress mucosal inflammation (157). SCFAs, such as butyrate and propionate, also induce Treg generation via HDAC inhibition (158). Microbiota-derived secondary bile acids have recently been shown to regulate colonic retinoic acid receptor-related orphan receptor gamma (RORγ)+ Treg induction and homeostasis (159).

Indoles, such as indole-3-aledhyde, signal through AhR in immune cells to regulate IL-22 production and promote mucosal immune homeostasis (160). Bacteria-derived B vitamins have an impact on many aspects of immunological maintenance (161). Vitamins B1 and B2 act as cofactors for enzymes involved in the TCA cycle and are important for immunometabolism and immune cell differentiation (161, 162). Vitamin B2 metabolite, 6-hydroxymethyl-8-D-ribityllumazine, bound to major histocompatibility complex (MHC) class I-related protein (MR1) on antigen-presenting cells (APC), activates mucosal-associated invariant T (MAIT) cells to promote production of pro-inflammatory interferon-gamma (IFNγ) and IL-17 (164). In contrast, the vitamin B9 metabolite, acetyl-6-formylpterin, inhibits activation of MAIT cells (165).

Vitamin B5 binds to GPR109A on macrophages and dendritic cells leading to an increase in anti-inflammatory cytokines and Treg differentiation (166). Vitamin B7 (biotin) suppresses the production of pro-inflammatory cytokines (167, 168). Vitamin B9 (folate) binds to the folate receptor 4 (FR4) on differentiated Tregs, promoting cell survival (161). Vitamin B12 is required for CD8+ T cell differentiation and NK cell activation (169).

As detailed, the intestinal microbiota is not functionally independent from the host mucosa, playing an important role in gut homeostasis. When there is a perturbation in this finely-balanced...
relationship, loss of mucosal barrier integrity and a rise in abnormal immune responses can occur leading to a risk of sustained pathogenic inflammation and development of disease.

3. Dysbiosis and Disease

Environmental changes as well as host genetic susceptibility can contribute to dysbiosis (170, 171). In a dysbiotic state, altered relative abundances of certain microbial species and/or microbiota-derived metabolites can lead to the disruption of intestinal barrier integrity and host immune responses. Dysregulated mucosal immune responses are often characterised by an upregulation of Th1, Th2, and Th17 cells and a downregulation of Tregs and IgA (172, 173). Dysbiosis is linked to the development of numerous disease states including IBD, rheumatoid arthritis (RA), multiple sclerosis (MS), and metabolic syndrome (172, 174)(Figure 4). However, it is worth noting that many of the studies to date, particularly those highlighting immunological pathways, have been solely based on findings from rodent models, which have inherent limitations (175).

**Figure 4. Linking dysbiosis and disease.** Several diseases have been linked to dysbiosis. A dysbiotic state is often characterised by a loss of beneficial microbes, increased levels of pathobionts and a decrease in microbial diversity. Changes in relative bacterial abundance, as well as microbial-derived metabolites, are thought to cause dysregulation in host gut permeability, leading to a compromised immune response and in turn the development of disease.

3.1 Inflammatory Bowel Disease

IBD is an umbrella term encompassing a group of complex chronic inflammatory disorders of the gastrointestinal tract (176). Most commonly in the form of Crohn’s disease (CD) and ulcerative colitis (UC), IBD has been associated with changes in gut microbiota. However, it is not clear whether these changes contribute to disease pathogenesis or develop because of disease-related inflammation. IBD patients exhibit a reduction in microbiota size, functional diversity, and stability compared to healthy controls. In general, the microbiome of IBD patients show a decrease in Firmicutes of the Clostridium leptum group, particularly *Faecalibacterium prausnitzii* (*F. prausnitzii*), and an increase in Bacteroidetes and Proteobacteria such as *Desulfovibrio desulfuricans* (*D. desulfuricans*) and *E. coli* (177-179). On average IBD patients harbour 25% less microbial genes than a healthy person (180).
The changes observed in the gut microbiome of IBD patients have been linked to bacteria known to have a role in either suppressing or promoting inflammation. Individuals with CD have a lower abundance of *F. prausnitzii*, a SCFA-producing bacterium, that promote good gut health through upregulation of Tregs and anti-inflammatory cytokines (181, 182). In humans, a reduction of *F. prausnitzii* is associated with an increased risk of postoperative recurrence of CD (182). Furthermore, in IBD patients, an increase in the abundance of the sulfate-reducing bacteria, such as *D. desulfuricans*, is attributed to increased production of hydrogen sulfate, which can damage intestinal epithelial cells and in turn induce mucosal inflammation (183, 184). Several human studies have also reported a mucosa-associated *E. coli* richness in CD patients (179, 185), leading to increased gut permeability and inflammation (186). Both human and murine models have found that a reduction in tryptophan levels are also associated with IBD (187, 188). In IBD patients, tryptophan serum levels were found to inversely correlate with IL-22 levels and disease activity (187).

### 3.2 Coeliac Disease

Coeliac disease, prevalent in 1%-2% of the global population, is an immune-mediated inflammatory disorder that primarily affects the small intestine and is initiated following ingestion of gluten in genetically predisposed individuals (189, 190). Research has suggested that dysbiosis plays a role in triggering coeliac disease with a dysregulated immune response and failure to maintain intestinal barrier integrity, leading to mucosal inflammation (191). However, like IBD, it remains unclear as to whether the dysbiotic state characteristic of coeliac disease is a cause or consequence of a dysregulated immune response.

As coeliac disease generally presents in childhood and young adulthood, most studies looking at a link between coeliac disease and the microbiome have focused on children (191). Rod shaped bacteria, including Clostridia, Prevotella, and Actinomycetes, are more frequently found in the small bowel of children with active coeliac compared to healthy controls (192). Whilst no consistent microbial signature has been determined for patients with coeliac disease, most studies report an imbalance between Gram-negative and Gram-positive bacteria, characterised by both an increase in Gram-negative Bacteroides and Proteobacteria, and a decrease in Gram-positive Lactobacilli and Bifidobacteria, which have a protective anti-inflammatory effect (193, 194). Experimental murine models have reported that some Bacteroidetes species are involved in the disruption of intestinal barrier integrity, exhibiting pro-inflammatory effects (46, 195, 196). Both mice and human studies have shown that Lactobacilli and Bifidobacteria may play a role in modifying the immunogenic potential of gluten, through breakdown of both gluten and its peptide derivatives (197, 198). For example, Lactobacilli can detoxify gliadin peptides after their partial digestion by human proteases. Both mice and human studies report that Bifidobacterium strains also play a role in reducing the epithelial permeability triggered by gluten, diminishing pro-inflammatory cytokine synthesis and decreasing jejunal barrier damage (199-201).

Whilst the exact mechanisms involved in coeliac disease remain unclear, studies in mice have shown that a dysbiotic microbiota can result in increased levels of LPS in the intestine, which result in a dysregulation of the immune response through the activation of both IELs and IECs, triggering the production of AMPs and mucin (202, 203). Additionally, mouse studies have linked alterations in microbial metabolites to the induction of Treg cells and dendritic cells, which produce IL-10 and retinoic acid and thereby contribute to the activation of various cellular inflammatory processes within the lamina propria (158, 204).

### 3.3 Other Autoimmune Diseases

RA is a systemic autoimmune disorder that results in joint destruction, affecting approximately 0.5%-1% of the global population (205). Patients with RA exhibit decreased gut microbial diversity and microbial gut dysbiosis characterised by an abundance of Prevotella, Lactobacilli and Collinsella (206-208). Mouse models show that Prevotella and Collinsella can induce a pro-inflammatory Th17 response and increase gut permeability (206). Colonisation of K/BxN mice, an established RA model, with segmented filamentous bacteria was shown to induce Th17 cell proliferation, ultimately leading to the differentiation of B cells and the production of autoantibodies (209). It is thought that these autoantibodies target joints, leading to the inflammation seen in RA.
MS is a neurodegenerative autoimmune disease that affects the central nervous system (CNS) (210). Whilst a typical microbiota phenotype for MS has not yet been described, patients with active disease generally exhibit decreased species richness, an abundance of Anaerostipes, Faecalibacteria and Psuedomonas, and decreased levels of Bacteroides, Prevotella, Parabacteroides and Adlercreutzia (211, 212). An autoimmune encephalomylitis (EAE) GF mouse model, which is also a model for MS, showed lower levels of IL-17 in both the gut and CNS, and an increase in peripheral Tregs (213). Furthermore, disease severity in EAE models is also closely related to altered intestinal permeability, reduced submucosa thickness and altered tight junction expression in IECs (214, 215).

3.4 Metabolic syndrome

Metabolic syndrome describes a group of risk factors, including obesity, hyperglycaemia, hypertension, and dyslipidaemia, which can lead to the development of various conditions including cardiovascular disease. The pathogenesis of metabolic syndrome is linked to a variety of factors such as insulin resistance, chronic low-grade inflammation in metabolic tissue, and oxidative stress (216). In recent years, gut dysbiosis has been identified as a risk factor for metabolic syndrome (217). It is believed that environmental factors, such as a high fat diet, linked to decreased microbial diversity, promotes both general and metabolic tissue inflammation that may lead to the development of metabolic syndrome.

The links between the gut microbiota and both obesity and type 2 diabetes (T2D) have been most extensively studied. Studies in mice have shown that transplantation of gut microbiota from obese to lean GF mice resulted in an obesogenic phenotype (218). Furthermore, GF mice fed a high fat, high sugar diet were found to be resistant to weight gain (219). Studies in humans suggest that compared to lean individuals, obese individuals have increased levels of Firmicutes and decreased levels of Bacteroidetes (220, 221). In both humans and murine models, Roux-en-Y gastric bypass surgery has been found to rapidly change the gut microbiota, with gut microbiota normalising close to non-obese controls (222, 223). Patients with T2D typically exhibit reduced microbiome diversity, reduced SCFA-producing bacteria, and an increased number of opportunistic pathogens (224). Rodent studies have found that SCFA play a key role in metabolic disorders, particularly in obesity and T2D. The SCFAs, propionate and acetate, were found to influence gut motility, intestinal transit rate and caloric energy extraction from the diet through GPR41 activation (225). Increased insulin sensitivity and increased satiety was also observed in mouse models, thought to be linked to the induction of glucagon-like peptide (GLP)-1 secretion through the activation of GPR43 and GPR41 (226). Butyrate provides energy to enterocytes by exerting a trophic effect and inducing GLP-2 synthesis that in turn strengthens the gut barrier function (227).

It has been suggested that the gut microbial dysbiosis experienced in metabolic disorders leads to impaired intestinal cell function and increased gut permeability, partly induced by a high fat diet (228). Rodent studies have reported an increase in Gram-negative bacteria, including Proteobacteria, leading to a local increase in LPS in the mucosal layer (229, 230). MAMPs and microbiota-derived metabolites, including LPS, can translocate through the epithelial layer and reach the lamina propria where they are internalised by phagocytes. Furthermore, it has been hypothesised that microbial gut dysbiosis impairs communication between phagocytes and other immune cells in animal models, allowing the translocation of bacterial components to metabolic tissue (231, 232). In the metabolic tissue of mice, bacterial components trigger inflammation by promoting the proliferation of preadipocytes and macrophages, increasing ILC3 frequency and increasing the infiltration of B and T lymphocytes. Associated pro-inflammatory cytokines can also contribute to reduced insulin signalling, exacerbating the effects of diabetes.

4. Microbiota-targeted therapies

As detailed previously, dysbiosis in the gut is implicated in multiple gastrointestinal and non-gastrointestinal diseases. Intervention aiming to ameliorate this pathological environment with the delivery of targeted beneficial or wholesale bacterial populations in the form of probiotics and faecal microbiota transplantation (FMT), respectively, has been in clinical practice for many years (233, 234). The various mechanisms by which probiotics and FMT exert their therapeutic effect has been reviewed in detail elsewhere (235-237), but centre on their interaction with the host mucosal immune system via MAMPs (238, 239) or extracellular vesicles (240-242), the surrounding microbiota via AMPs (243),
microbial cross-feeding (244) or nutrient competition, and their contribution to the broader mucosal metabolic environment (118, 148). Here we review the latest developments and innovations in probiotics and FMT.

4.1 Probiotics

The main probiotic genera, including Lactobacilli, Bifidobacteria, Saccharomyces and Streptococci, as well as combination commercial probiotics, have been researched extensively and touted as potential therapies for many diseases or symptoms (245). Certain probiotic strains have discrete effects on mucosal immune function, such as that seen with *Lactobacillus plantarum* TIPN1010 which modulates gene transcription pathways related to cell-cell adhesion and mucosal healing processes (238). However, robust clinical data to support their use remains limited, with systematic reviews in IBD (246-248), Irritable bowel syndrome (IBS) (249) and *C. difficile*-associated diarrhea (CDAD)(250) showing neutral or only qualified evidence for use. Similarly, practice guidelines do not recommend the routine use of probiotics (233), partly due to uncertainty regarding species or strain-dependent effects (251, 252).

Recent advances in genomic sequencing and metabolic modelling have offered a way to reduce microbial uncertainty and the chance to optimise probiotic use through genetic engineering tools such as CRISPR-Cas (253-256). For example, genetic modification of *Lactobacillus casei* (*L. casei*) to overexpress the *mcrA* gene, and so enhance bioactive compound production, such as conjugate linoleic acid, can result in elimination of *Campylobacter jejuni*, an important diarrhoea-associated pathogen (257). As well as optimising established probiotic species such as *L. casei*, confirmation of species such as *Akkermansia muciniphila* (*A. muciniphila*) as probiotic therapeutic candidates has become possible through the use of genome-scale modelling. Using this method, the complete microbial genome sequence can be screened to predict genes that influence particular metabolic pathways (258). For *A. muciniphila*, genes linked to sugar degradation and vitamin biosynthesis, as well as SCFA production, were predicted using this approach and validated by transcriptomic and proteomic analysis in vitro (259). Antibiotic resistance and metabolic variation can also be assessed by whole-genome assembly undertaken on patient-derived stool samples (260). Genomic sequencing technology has also been used to identify individuals resistant to probiotic colonisation at the mucosal level (261), allowing therapy to then be tailored, reducing treatment variability currently seen with probiotics (262).

Overall, whilst significant advances in probiotic therapy have been made, there is a need for a greater understanding of probiotic formulation, in addition to a requirement for more robust human clinical trial data to justify its routine use.

4.2 Postbiotics

An important additional consideration regarding probiotic preparations is the intrinsic effect of microbial cell surface components and metabolites. Whereas, by definition, probiotics are live microorganisms (263), there is also a role for postbiotics, as inanimate microorganisms and/or their components (264), prepared specifically for their health benefits on the host. These narrow criteria exclude purified microbial metabolites applied in isolation and instead focus on thermal inactivation and quantification of products that possess microbial effector molecules such as bile salt hydrolase (265) and exopolysaccharides (239).

Murine studies have shown the effect of postbiotics on gastrointestinal mucosa in a *Citrobacter*-induced colitis model (266), whereas the mechanistic impact on mucosal inflammation in humans is more limited to specific metabolites such as butyrate as in the case of diversion colitis (267). However, clinical studies focussing on subjective outcomes such as symptom scores have shown benefit of postbiotics in IBS (268).

To date, the application of postbiotics in gastrointestinal disease remains limited with the mainstay of evidence (269, 270) and regulation (271), centred on secondary prevention of respiratory infections. Further mechanistic and clinical trial data is required to characterise the effect of specific postbiotics on gastrointestinal inflammation.

4.3 Faecal Microbiota Transplantation

...
FMT, the delivery of donor stool into the gastrointestinal tract of a patient, is an established and guideline-supported intervention for recurrent *C. difficile* infection (rCDI) (234, 272, 273), independent of route of delivery (274), and a potential option in severe primary CDI (275). Meta-analysis has indicated a positive association between FMT and the treatment of IBD, particularly with active UC (276, 277). Further trials are currently underway (278) to confirm FMT efficacy before being adopted into routine clinical practice (279). Similarly, with CD, there is evidence supporting the benefits of FMT (280), however, it has not yet been recommended for clinical use (281). Evidence remains lacking for routine use of FMT in IBS (282) with evidence for only conditional use in metabolic syndrome (283, 284) and hepatic encephalopathy (285). The use of FMT in non-gastrointestinal diseases is an area of ongoing study with randomised clinical trials in type 1 diabetes showing promise (286). FMT clinical trials are also underway to assess effectiveness in treating Coeliac disease (NCT 04014413), RA (NCT03944096), Sjögren’s syndrome (NCT03926286) and MS (NCT03183869; NCT03975413; NCT04150549), building upon prior animal and uncontrolled human studies (287). It is in malignancy, and specifically anti-cancer immunotherapies, where microbiota and their manipulation have shown great promise, building on evidence that certain genera, for example, Bifidobacteria (288) or Bacteroides (289), can affect the efficacy of malignant melanoma treatments. A recent clinical trial revealed that some patients refractory to anti-programmed cell death protein 1 (PD-1) immunotherapy could overcome this resistance to therapy by undergoing FMT from donors who were responders to the same anti-PD-1 immunotherapy (290). PD-1 is an immune checkpoint receptor on T cells that prevents overstimulation of immune responses and contributes to the maintenance of immune tolerance to self-antigens. The fact that FMT impacts on anti-PD-1 melanoma therapy demonstrates that the composition of the microbiota influences host systemic immune responses. FMT is now being applied to metastatic hormone-resistant prostate cancer (NCT04116775) and to ameliorate chemotherapy-induced toxicity (NCT04040712).

An important factor in FMT is the role of viruses and mycobacteria given that whole stool transplantation involves a transfer of these microorganisms to the new host along with bacteria. Bacteriophages contribute to host immunity by adhering to mucosal mucus creating an additional antimicrobial layer that reduces bacterial attachment and colonisation of the mucosa (291). Both Caudovirales (292) and Saccharomyces (293) have been shown as important drivers for successful treatment of rCDI by FMT. Faecal filtrate transfer (FFT), a supernatant composed of bacterial debris, AMPs, metabolic products and oligonucleotides, but not live bacteria, was also seen to improve outcomes in rCDI (294).

A limitation of widespread FMT use outside of the trial setting is the conceptual acceptability of single or pooled donor stool being transferred to a patient. Synthetic microbiomes can be cultured from donors and purified, or compiled from metagenomic studies (295). Purified intestinal bacterial culture have been shown to be as effective in treating rCDI in a proof-of-principle study (296). A recent randomised-controlled trial reported that a 12-strain bacterial mixture cultured from donor stool was inferior to conventional FMT but equivalent to using vancomycin for the treatment of rCDI (297). FMT using freeze-dried or lyophilised matter has been shown in observational studies to also be effective in treating rCDI (298), with a propagated, lyophilised and encapsulated formulation currently under investigation in clinical trials for the treatment of rCDI (NCT02865616), UC (NCT03832400) and other diseases. These technologies, if efficacy is confirmed, herald the opportunity of a ‘post-FMT’ treatment model centred on highly selected donors yielding a purified, standardised and cryopreserved microbiota preparation for systematic clinical use.

**Conclusion**

The microbiome is a metabolically and immunologically active presence within the gastrointestinal tract that plays a vital role in the maintenance of human health. This population of highly diverse microorganisms is shaped by numerous factors, most notably, diet and the use of medications such as antibiotics. The intestinal mucosa provides an important interface between the microbiota and host, where the microbiota not only aids development of effective host immune responses against pathogens and injury but also limits excessive mucosal inflammation to promote tolerance and stability of the gut environment. Microbial components and microbial-derived metabolites contribute to both mucosal barrier integrity and the regulation of underlying immune responses to preserve intestinal homeostasis. When there is a loss of this balanced relationship, as seen in dysbiosis, then there is a risk of sustained
pathogenic inflammation and the development of numerous diseases. As our understanding of the microbiome and microbiota-host interactions has improved, so has our ability to harness members of the microbiota to reverse dysbiosis, reduce mucosal inflammation, and prevent disease progression. The outcome of ongoing clinical trials and mechanistic studies will hopefully extend our current knowledge of the microbiome and further our understanding of the role it plays in mucosal inflammation.

Author Contributions

DJS, SI, and GSR wrote the manuscript. DJS produced the figures. AMS and FZR revised the manuscript. All authors read and approved the final manuscript.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

We would like to thank NIHR Biomedical Research Centre at University College London NHS Foundation and University College London (Grant BRC727/OHD/AS/110380) for funding DJS and AMS. GSR is supported by a Crohn’s & Colitis UK Fellowship (Grant ID: 2019-4 Smith (Sebepos-Roger); Award number 179344).

References

1. Dethlefsen L, McFall-Ngai M, Relman DA. An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature. 2007;449(7164):811-8.
2. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature. 2007;449(7164):804-10.
3. Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016;14(8):e1002533.
4. Koskinen K, Pausan MR, Perras AK, Beck M, Bang C, Mora M, et al. First Insights into the Diverse Human Archaeome: Specific Detection of Archaea in the Gastrointestinal Tract, Lung, and Nose and on Skin. mBio. 2017;8(6).
5. Kumata R, Ito J, Takahashi K, Suzuki T, Sato K. A tissue level atlas of the healthy human virome. BMC Biol. 2020;18(1):55.
6. Ghannoum MA, Jurevic RJ, Mukherjee PK, Cui F, Sikaroodi M, Naqvi A, et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog. 2010;6(1):e1000713.
7. Nieves-Ramirez ME, Partida-Rodriguez O, Laforest-Lapointe I, Reynolds LA, Brown EM, Valdez-Salazar A, et al. Asymptomatic Intestinal Colonization with Protist Blastocystis Is Strongly Associated with Distinct Microbiome Ecological Patterns. mSystems. 2018;3(3).
8. Tierney BT, Yang Z, Luber JM, Beaudin M, Wibowo MC, Baek C, et al. The Landscape of Genetic Content in the Gut and Oral Human Microbiome. Cell Host Microbe. 2019;26(2):283-95 e8.
9. Bharti R, Grimm DG. Current challenges and best-practice protocols for microbiome analysis. Brief Bioinform. 2019.
10. Integrative HMPRNC. The Integrative Human Microbiome Project. Nature. 2019;569(7758):641-8.
11. Zhao L, Ni Y, Su M, Li H, Dong F, Chen W, et al. High Throughput and Quantitative Measurement of Microbial Metabolome by Gas Chromatography/Mass Spectrometry Using Automated Alkyl Chloroformate Derivatization. Anal Chem. 2017;89(10):5565-77.
12. Mas-Lloret J, Obon-Santacana M, Ibanez-Sanz G, Guino E, Pato ML, Rodriguez-Moranta F, et al. Gut microbiome diversity detected by high-coverage 16S and shotgun sequencing of paired stool and colon sample. Sci Data. 2020;7(1):92.
754

with gut microbial enterotypes. Science. 2011;334(6052):105

753

centres. Microbiology. 2011;157(5):1385

752

intestinal microbiota after the introduction of first complementary foods in infant samples from five European

751

38.

37.

36.

35.

34.

33.

32.

31.

30.

29.

28.

27.

26.

25.

24.

23.

22.

21.

20.

19.

18.

17.

16.

15.

14.

13.

12.

11.

10.

9.

8.

7.

6.

5.

4.

3.

2.

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}

1.}
40. Reddy BS, Weisburger JH, Wynder EL. Effects of high risk and low risk diets for colon carcinogenesis on fecal microflora and steroids in man. J Nutr. 1975;105(7):878-84.
41. Drasar BS, Crowther JS, Goddard P, Hawksworth G, Hill MJ, Peach S, et al. The relation between diet and the gut microflora in man. Proceedings of the Nutrition Society. 1973;32(2):49-52.
42. Bisanz JE, Upadhyay V, Turnbaugh JA, Ly K, Turnbaugh PJ. Meta-Analysis Reveals Reproducible Gut Microbiome Alterations in Response to a High-Fat Diet. Cell Host & Microbe. 2019;26(2):265-72.e4.
43. Moreira AP, Texeira TF, Ferreira AB, Peluzio Mdo C, Alfenas Rde C. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr. 2012;108(5):801-9.
44. Gerasimidis K, Bryden K, Chen X, Papachristou E, Verney A, Roig M, et al. The impact of food additives, artificial sweeteners and domestic hygiene products on the human gut microbiome and its fibre fermentation capacity. European Journal of Nutrition. 2020;59(7):3213-30.
45. Partridge D, Lloyd KA, Rhodes JM, Walker AW, Johnstone AM, Campbell BJ. Food additives: Assessing the impact of exposure to permitted emulsifiers on bowel and metabolic health - introducing the FADiets study. Nutr Bull. 2019;44(4):329-49.
46. Sydora BC, MacFarlane SM, Walker JW, Dmytrash AL, Churchill TA, Doyle J, et al. Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse. Inflammatory Bowel Diseases. 2007;13(8):947-54.
47. Del Chierico F, Vernocchi P, Dallapiccola B, Putignani L. Mediterranean diet and health: food effects on gut microbiota and disease control. Int J Mol Sci. 2014;15(7):11678-99.
48. Garcia-Mantra I, Selma-Royo M, Alcantara C, Collado MC. Shifts on Gut Microbiota Associated to Mediterranean Diet Adherence and Specific Dietary Intakes on General Adult Population. Frontiers in Microbiology. 2018;9(890).
49. Heiman ML, Greenway FL. A healthy gastrointestinal microbiome is dependent on dietary diversity. Molecular Metabolism. 2016;5(5):317-20.
50. Zarripa A, Chaix A, Yoosop S, Panda S. Diet and feeding pattern affect the diurnal dynamics of the gut microbiome. Cell Metab. 2014;20(6):1006-17.
51. Kaczmarek JL, Musaad SM, Holscher HD. Time of day and eating behaviors are associated with the composition and function of the human gastrointestinal microbiota. The American Journal of Clinical Nutrition. 2017;106(5):1220-31.
52. De Filippis F, Vitaglione P, Cuomo R, Berni Canani R, Ercolini D. Dietary Interventions to Modulate the Gut Microbiome—How Far Away Are We From Precision Medicine. Inflammatory Bowel Diseases. 2018;24.
53. Zhang C, Li S, Yang L, Huang P, Li W, Wang S, et al. Structural modulation of gut microbiota in life-long calorie-restricted mice. Nature Communications. 2013;4(1):2163.
54. Santacruz A, Marcos A, Wännerg J, Marti A, Martin-Matillas M, Campoy C, et al. Interplay Between Weight Loss and Gut Microbiota Composition in Overweight Adolescents. Obesity. 2009;17(10):1906-15.
55. Kurup K, Matyi S, Giles CB, Wren JD, Jones K, Ericsson A, et al. Calorie restriction prevents age-related changes in the intestinal microbiota. Aging (Albany NY). 2021;13(5):6298-329.
56. Zheng X, Wang S, Jia W. Calorie restriction and its impact on gut microbial composition and global metabolism. Front Med. 2018;12(6):344-44.
57. Klingsenstih NJ, Coopersmith CM. The Gut as the Motor of Multiple Organ Dysfunction in Critical Illness. Crit Care Clin. 2016;32(2):203-12.
58. Nguyen LH, Örtqvist AK, Cao Y, Simon TG, Roelstraete B, Song M, et al. Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. The Lancet Gastroenterology & Hepatology. 2020;5(11):986-95.
59. Kim DH, Han K, Kim SW. Effects of Antibiotics on the Development of Asthma and Other Allergic Diseases in Children and Adolescents. Allergy Asthma Immunol Res. 2018;10(5):457-65.
60. Bhalodi AA, van Engelen TSR, Virk HS, Wiersinga WJ. Impact of antimicrobial therapy on the gut microbiome. J Antimicrob Chemother. 2019;74(Suppl 1):i6-i15.
61. Panda S, El khader I, Casellas F, López Vivancos J, García Cors M, Santiago A, et al. Short-term effect of antibiotics on human gut microbiota. PLoS One. 2014;9(4):e95476.
62. Scott NA, Andrusialte A, Andersen P, Lawson M, Alcon-Giner C, Leclaire C, et al. Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci Transl Med. 2018;10(464).
63. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. Isme J. 2007;1(1):56-66.
64. Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836.
65. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108 Suppl 1(Suppl 1):4554-61.

66. Isaac S, Scher JU, Djukovic A, Jiménez N, Littman DR, Abramson SB, et al. Short- and long-term effects of oral vancomycin on the human intestinal microbiota. J Antimicrob Chemother. 2017;72(1):128-36.

67. Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, Kootte RS, et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. Journal of Hepatology. 2014;60(4):824-31.

68. Vich Vila A, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje AR, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature Communications. 2020;11(1):362.

69. Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69(8):1510-9.

70. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proceedings of the National Academy of Sciences. 2010;107(26):11971-5.

71. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. The American Journal of Clinical Nutrition. 1999;69(5):1035s-45s.

72. Cahenzli J, Koller W, Wyss M, Geuking MB, McCoy KD. Intestinal microbial diversity during early-life colonization shapes long-term IgE levels. Cell Host Microbe. 2013;14(5):559-70.

73. Jakobsson HE, Abrahamsson TR, Jenmalm MC, Harris K, Quince C, Jernberg C, et al. Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by caesarean section. Gut. 2014;63(4):559-66.

74. Stewart CJ, Ajami NJ, O'Brien JL, Hutchinson DS, Smith DP, Wong MC, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature. 2018;562(7728):583-8.

75. Agans R, Riggsbee L, Kenche H, Michail S, Khamis HJ, Pally O. Distal gut microbiota of adolescent children is different from that of adults. FEMS Microbiology Ecology. 2011;77(2):404-12.

76. Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, Chinwalla AT, et al. Structure, function and diversity of the healthy human microbiome. nature. 2012;486(7402):207.

77. Quigley EM. Gut bacteria in health and disease. Gastroenterol Hepatol (N Y). 2013;39(9):560.

78. Odamaki T, Kato K, Sugahara H, Hashikura S, Takahashi S, Xiao J-z, et al. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. BMC microbiology. 2016;16(1):1-12.

79. Ragonnaud E, Biragyn A. Gut microbiota as the key controllers of “healthy” aging of elderly people. Immunity & Ageing. 2021;18(1):2.

80. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poulet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proceedings of the National Academy of Sciences. 2010;107(33):14691-6.

81. Grzeskowiak T, Collado MC, Mangani C, Maleta K, Laitinen K, Ashorn P, et al. Distinct gut microbiota in southeastern African and northern European infants. J Pediatr Gastroenterol Nutr. 2012;54(6):812-9.

82. Gomez A, Petrzelkova Klara, Zingaretti J, Burns Michael B, Yeoman Carl J, Amato Katherine R, Vickova K, et al. Gut Microbiome of Coexisting Baaka Pygmies and Bantu Reflects Geographical and Biotic Subsistence Patterns. Cell Reports. 2016;14(9):2142-53.

83. Morton ER, Lynch J, Froment A, Lafosse S, Heyer E, Przeworski M, et al. Variation in Rural African Gut Microbiota Is Strongly Correlated with Colonization by Entamoeba and Subsistence. PLoS Genet. 2015;11(11):e1005658.

84. Greenhill AR, Tsuji H, Ogata K, Natsuhara K, Morita A, Soli K, et al. Characterization of the gut microbiota of Papua New Guineans using reverse transcription quantitative PCR. PLoS One. 2015;10(2):e0117427.

85. Obregon-Tito AJ, Tito RY, Meltalf J, Sankaranarayanan K, Clemente JC, Ursell LK, et al. Subsistence strategies in traditional societies distinguishing gut microbiomes. Nature Communications. 2015;6(1):6505.

86. Schnorr SL, Candela M, Rampelli S, Centanni M, Consolandi C, Basaglia G, et al. Gut microbiome of the Hadza hunter-gatherers. Nature Communications. 2014;5(1):3654.

87. Shreiner A, Huffnagle GB, Noverr MC. The "Microflora Hypothesis" of allergic disease. Adv Exp Med Biol. 2008;635:113-34.

88. Jha AR, Davenport ER, Gautam Y, Bhandari D, Tandukar S, Ng KM, et al. Gut microbiome transition across a lifestyle gradient in Himalaya. PLOS Biology. 2018;16(11):e2005396.

89. Martino D. The Effects of Chlorinated Drinking Water on the Assembly of the Intestinal Microbiome. Challenges. 2019;10(1):10.

90. Mowat AM. To respond or not to respond - a personal perspective of intestinal tolerance. Nat Rev Immunol. 2018;18(6):405-15.
Diseases. Front Immunol. 2019;10:277.

Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut. 1980;21(9):793-800.

Singh R, Chandrashekharappa S, Bodduluri SR, Baby BV, Hegde B, Kotla NG, et al. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. Nat Commun. 2019;10(1):228-33.

Shimada Y, Kinoshita M, Harada K, Mizutani M, Masahata K, Kayama H, et al. Commensal bacteria maintain intestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity. 2014;41(2):251-8.

Robinson K, Deng Z, Hou Y, Zhang G. Regulation of the Intestinal Barrier Function by Host Defense Peptides. Front Vet Sci. 2015;2:57.

Schroeder BO. Fight them or feed them: how the intestinal mucus layer manages the gut microbiota. Adv Drug Deliv Rev. 2011;63(13):1450-7.

Hilchie AL, Wuerth K, Hancock RE. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol. 2013;9(12):761-8.

Mansour SC, Pena OM, Hancock RE. Host defense peptides: front-line immunomodulators. Trends Immunol. 2014;35(9):443-50.

Takagi K, Nakai S, Nakamura S, Ihori K, Aoyagi FS, Seeberger PH, et al. Symbionts exploit the mammalian activated protein kinase pathway. J Cell Biochem. 2014;115(10):2385-95.
118. Kelly CI, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, et al. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe. 2015;17(5):662-71.

119. Nepelska M, de Wouters T, Jacouton E, Begue-Crespe F, Lapaque N, Dore J, et al. Commensal gut bacteria modulate phosphorylation-dependent PPARGamma transcriptional activity in human intestinal epithelial cells. Sci Rep. 2017;7:43199.

120. Ritzhaupt A, Wood IS, Ellis A, Hosie KB, Shirazi-Beechey SP. Identification and characterization of a monocarboxylate transporter (MCT1) in pig and human colon: its potential to transport L-lactate as well as butyrate. J Physiol. 1998;513 (Pt 3):719-32.

121. Sivaprakasam S, Bhutia YD, Yang S, Ganapathy V. Short-Chain Fatty Acid Transporters: Role in Colonic Homeostasis. Compr Physiol. 2017;8(1):299-314.

122. Alex S, Lange K, Amolo T, Grinstead JS, Haakonsson AK, Szalowska E, et al. Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor gamma. Mol Cell Biol. 2013;33(7):1303-16.

123. Sivaprakasam S, Prasad PD, Singh N. Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. Pharmacol Ther. 2016;164:144-51.

124. Macia L, Tan J, Vieira AT, Leach K, Stanley D, Luong S, et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun. 2015;6:6734.

125. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278(13):11312-9.

126. Chen B, Chen H, Shu X, Yin Y, Li J, Qin J, et al. Presence of Segmented Filamentous Bacteria in Human Children and Its Potential Role in the Modulation of Human Gut Immunity. Front Microbiol. 2018;9:1403.

127. Burger-van Paassen N, Vincent A, Puiman PJ, van der Sluis B, Bouma J, Boehm G, et al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J. 2009;420(2):211-9.

128. Zhao Y, Chen F, Wu W, Sun M, Bilotta AJ, Yao S, et al. GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3.

129. Mucosal Immunol. 2018;11(3):752-62.

130. Miyamoto J, Mizukura T, Park SB, Kishino S, Kimura I, Hirano K, et al. A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway. J Biol Chem. 2015;290(5):2902-18.

131. Yao B, He J, Yin X, Shi Y, Wan J, Tian Z. The protective effect of lithocholic acid on the intestinal epithelial barrier is mediated by the vitamin D receptor via a SIRT1/Nrf2 and NF-kappaB dependent mechanism in Caco-2 cells. Toxicol Lett. 2019;316:109-18.

132. Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science. 2016;352(6285):539-44.

133. Bauern H, Horowitz RE, Levenson SM, Popper H. The response of the lymphatic tissue to the microbial flora. Studies on germfree mice. Am J Pathol. 1963;42:471-83.

134. Umesaki Y, Setoyama H, Matsumoto S, Okada Y. Expansion of alpha beta T-cell receptor-bearing intestinal intraepithelial lymphocytes after microbial colonization in germ-free mice and its independence from thymus. Immunology. 1993;79(1):32-7.

135. Hapfelmeier S, Lawson MA, Slack E, Kirundi JK, Stoel M, Heikenwalder M, et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science. 2010;328(5986):1705-9.

136. Gomez de Aguero M, Ganal-Vonarburg SC, Fuhrer T, Rupp S, Uchimura Y, Li H, et al. The maternal microbiota drives early postnatal innate immune development. Science. 2016;351(6279):1296-302.

137. Ivanov, II, Frutos Rde L, Manel N, Yoshinaga K, Rikfin DB, Sartor RB, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008;4(4):337-49.

138. Ivanov, II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139(3):485-98.

139. Tan TG, Sevik E, Geva-Zatorsky N, Kua L, Naskar D, Teng F, et al. Identifying species of symbiotic bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice. Proc Natl Acad Sci U S A. 2016;113(50):E8141-E50.

140. Atarashi K, Tanoue T, Ando M, Kamada N, Nagano Y, Narushima S, et al. Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells. Cell. 2015;163(2):367-80.
Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107-18.

An D, Oh SF, Olszak T, Neves JF, Avci FY, Erturk-Hasdemir D, et al. Sphingolipids from a symbiotic microbe regulate homeostasis of host natural killer T cells. Cell. 2014;156(1-2):123-33.

Wesemann DR, Portuguese AJ, Meyers RM, Gallagher MP, Cluff-Jones K, Magee JM, et al. Microbial colonization influences early B-lineage development in the gut lamina propria. Nature. 2013;501(7465):112-5.

Levy M, Thaiss CA, Zeevi D, Dohnalova L, Zilberman-Schapira G, Mahdi JA, et al. Microbiota-Modulated Metabolites Shape the Intestinal Microenvironment by Regulating NLRP6 Inflammasome Signaling. Cell. 2015;163(6):1428-43.

Seo SU, Kamada N, Munoz-Planillo R, Kim YG, Kim D, Koizumi Y, et al. Distinct Commensals Induce Interleukin-1beta via NLRP3 Inflammasome in Inflammatory Monocytes to Promote Inflammatory Inflammation in Response to Injury. Immunity. 2015;42(4):744-55.

Wolf AJ, Underhill DM. Peptidoglycan recognition by the innate immune system. Nat Rev Immunol. 2018;18(4):243-54.

Bain CC, Bravo-Blas A, Scott CL, Perdigueró EG, Geissmann F, Henri S, et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol. 2014;15(10):929-37.

Danne C, Ryzhakov G, Martinez-Lopez M, Ilott NE, Franchini F, Cuskin F, et al. A Large Polysaccharide Produced by Helicobacter hepaticus Induces an Anti-inflammatory Gene Signature in Macrophages. Cell Host Microbe. 2017;22(6):733-45 e5.

Schulthess J, Pandey S, Capitani M, Rue-Albrecht KC, Arnold I, Franchini F, et al. The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages. Immunity. 2019;50(2):432-45 e7.

Wu K, Yuan Y, Yu H, Dai X, Wang S, Sun Z, et al. The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. Blood. 2020;136(4):501-15.

Yue C, Yang X, Li J, Chen X, Zhao X, Chen Y, et al. Trimethylamine N-oxide prime NLRP3 inflammasome via inhibiting ATG16L1-induced autophagy in colonic epithelial cells. Biochem Biophys Res Commun. 2017;490(2):541-51.

Sonnenberg GF, Artis D. Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat Med. 2015;21(7):698-708.

Ganal M, Wiegmann K, Schramm S, Gluschko A, Herb M, Utermohlen O, et al. Riboflavin (vitamin B2) deficiency impairs NADPH oxidase 2 (Nox2) priming and defense against Listeria monocytogenes. Eur J Immunol. 2014;44(3):728-41.
164. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature. 2012;491(7426):717-23.
165. Eckle SB, Birkinshaw RW, Kostenko L, Corbett AJ, McWilliam HE, Reantragoor R, et al. A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. J Exp Med. 2014;211(8):1585-600.
166. Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014;40(1):128-39.
167. Agrawal S, Agrawal A, Said HM. Biotin deficiency enhances the inflammatory response of human dendritic cells. Am J Physiol Cell Physiol. 2016;311(3):C386-91.
168. Skupsky J, Sabui S, Hwang M, Nakasaki M, Cahalan MD, Said HM. Biotin Supplementation Ameliorates Murine Colitis by Preventing NF-kappaB Activation. Cell Mol Gastroenterol Hepatol. 2020;9(4):S57-67.
169. Tamura J, Kubota K, Murakami H, Sawamura M, Matsushima T, Tamura T, et al. Immunomodulation by vitamin B12: augmentation of CD8+ T lymphocytes and natural killer (NK) cell activity in vitamin B12-deficient patients by methyl-B12 treatment. Clin Exp Immunol. 1999;116(1):28-32.
170. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? science. 2010;330(6012):1768-73.
171. Harmsen HJ, de Goffau MC. The human gut microbiota. Microbiota of the Human Body. 2016:95-108.
172. DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current Understanding of Dysbiosis in Disease in Human and Animal Models. Inflammatory Bowel Diseases. 2016;22(5):1137-50.
173. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-41.
174. Das B, Nair GB. Homeostasis and dysbiosis of the gut microbiome in health and disease. Journal of biosciences. 2019;44(5):1-8.
175. Nguyen TLA, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? Dis Model Mech. 2015;8(1):1-16.
176. Mulder DJ, Noble AJ, Justinich CJ, Duffin JM. A tale of two diseases: the history of inflammatory bowel disease. J Crohns Colitis. 2014;8(5):341-8.
177. Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, et al. A microbial signature for Crohn’s disease. Gut. 2017;66(5):813-22.
178. Gevers D, Kugathasan S, Denson Lee A, Vázquez-Baeza Y, Van Treuren W, Ren B, et al. The Treatment- Naive Microbiome in New-Onset Crohn’s Disease. Cell Host & Microbe. 2014;15(3):382-92.
179. Martinez-Medina M, Aldeguer X, Lopez-Siles M, Gonzalez-Huix F, Lopez-Olivo C, Dahbi G, et al. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn’s disease. Inflamm Bowel Dis. 2009;15(6):872-82.
180. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65.
181. Willing B, Halfvarson J, Dicksved J, Rosenquist M, Järnerot G, Engstrand L, et al. Twin studies reveal specific imbalances in the mucosaassociated microbiota of patients with ileal Crohn’s disease. Inflammatory bowel diseases. 2009;15(5):653-60.
182. Sokol H, Pigneur B, Watterlot L, Lakhdi O, Bermúdez-Humarán LG, Gratadoux J-J, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences. 2008;105(43):16731-6.
183. Loubinoux I, Bronowicki J-P, Pereira IAC, Mougenel J-L, Le Faou AE. Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. FEMS Microbiology Ecology. 2002;40(2):107-12.
184. Jia W, Whitehead RN, Griffiths L, Dawson C, Bai H, Waring RH, et al. Diversity and distribution of sulphate-reducing bacteria in human faeces from healthy subjects and patients with inflammatory bowel disease. FEMS Immunol Med Microbiol. 2012;65(1):55-68.
185. Darfeuille-Michaud A, Boudeva J, Bulos P, Neut C, Glasser AL, Barnich N, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127(2):412-21.
186. Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut. 2018;67(3):574-87.
187. Nikolova S, Schulte B, Al-Massad N, Thieme F, Schulte DM, Bethge J, et al. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases. Gastroenterology. 2017;153(6):1504-16.e2.
188. Lamas B, Richard ML, Leducq V, Pham H-P, Michel M-L, Da Costa G, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nature Medicine. 2016;22(6):598-605.
1100 189. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823-36.e2.
1101 190. De Re V, Magris R, Cannizzaro R. New Insights into the Pathogenesis of Celiac Disease. Frontiers in Medicine. 2017;4(137).
1102 191. Akobeng AK, Singh P, Kumar M, Al Khodor S. Role of the gut microbiota in the pathogenesis of celiac disease and potential therapeutic implications. European Journal of Nutrition. 2020;59(8):3369-90.
1103 192. Collado MC, Calabuig M, Sanz Y. Differences between the fecal microbiota of celiac infants and healthy controls. Curr Issues Intest Microbiol. 2007;8(1):9-14.
1104 193. De Palma G, Nadal I, Medina M, Donat E, Ribes-Koninckx C, Calabuig M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with celiac disease in children. BMC Microbiology. 2010;10(1):63.
1105 194. Sanz Y, Sánchez E, Marzotto M, Calabuig M, Torrianis D, Dellaglio F. Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis. FEMS Immunology & Medical Microbiology. 2007;51(3):562-8.
1106 195. Sánchez E, Laparra JM, Sanz Y. Discerning the role of Bacteroides fragilis in celiac disease pathogenesis. Applied and environmental microbiology. 2012;78(18):6507-15.
1107 196. Shiba T, Aiba Y, Ishikawa H, Usihiyama A, Takagi A, Mine T, et al. The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol. 2003;47(6):371-8.
1108 197. Caminero A, Herrán AR, Nistal E, Pérez-Andrés J, Vaquero L, Vivas S, et al. Diversity of the cultivable human gut microbiome involved in gluten metabolism: isolation of microorganisms with potential interest for coeliac disease. FEMS Microbiology Ecology. 2014;88(2):309-19.
1109 198. Olives M, Laparra M, Sanz Y. Influence of Bifidobacterium longum CECT 7347 and gliadin peptides on intestinal epithelial cell proteome. J Agric Food Chem. 2011;59(14):7666-71.
1110 199. Lindfors K, Blomqvist T, Juuti-Uusitalo K, Stenman S, Venäläinen J, Mäki M, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol. 2008;152(3):552-8.
1111 200. Medina M, De Palma G, Ribes-Koninckx C, Calabuig M, Sanz Y. Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients. Journal of Inflammation. 2008;5(1):19.
1112 201. Laparra JM, Olives M, Gallina O, Sanz Y. Bifidobacterium longum CECT 7347 modulates immune responses in a gliadin-induced enteropathy animal model. PLoS One. 2012;7(2):e30744.
1113 202. Chen VL, Kasper DL. Interactions between the intestinal microbiota and innate lymphoid cells. Gut Microbes. 2014;5(1):129-40.
1114 203. Moro K, Koyasu S. Innate lymphoid cells, possible interaction with microbiota. Seminars in Immunopathology. 2015;37(1):27-37.
1115 204. Hrncir T, Stepankova R, Kozakova H, Hudcovic T, Tlaskalova H. Investigation of the role of segmented filamentous bacteria in celiac disease. FEMS Immunology & Medical Microbiology. 2007;51(3):562-8.
1116 205. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4 Suppl 3(Suppl 3):S265-S72.
1117 206. Chen J, Wright K, Davis JM, Jerald M, Marietta EV, Murray J, et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016;8(1):43-.
1118 207. Liu X, Zou Q, Zeng B, Fang Y, Wei H. Analysis of fecal Lactobacillus community structure in patients with early rheumatoid arthritis. Current microbiology. 2013;67(2):170-6.
1119 208. Maeda Y, Kurakawa T, Umemoto E, Motooka D, Ito Y, Gotoh K, et al. Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis & Rheumatology. 2016;68(11):2646-61.
1120 209. Wu H-J, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32(6):815-27.
1121 210. Wallin MT, Culpepper WJ, Nichols E, Bhutta ZA, Gebrehiwot TT, Hay SI, et al. Global, regional, and national burden of multiple sclerosis 1990–2013:2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019;18(3):269-85.
1122 211. Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6:28484.
1123 212. Cantarel BL, Waubant E, Chehoud C, Kuczynski J, DeSantis TZ, Warrington J, et al. Gut microbiota in multiple sclerosis: possible influence of immunomodulators. J Investig Med. 2015;63(5):729-34.
1157 213. Lee YK, Menezis JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2011;108 Suppl 1(Suppl 1):4615-22.

1158 214. Nouri M, Bredberg A, Weström B, Lavasani S. Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells. PLoS One. 2014;9(9):e106335.

1159 215. Secher T, Kassem S, Benamar M, Bernard I, Boury M, Barreau F, et al. Oral Administration of the Probiotic Strain Escherichia coli Nissle 1917 Reduces Susceptibility to Neuroinflammation and Repairs Experimental Autoimmune Encephalomyelitis-Induced Intestinal Barrier Dysfunction. Front Immunol. 2017;8:1096.

1160 216. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5-6):231-7.

1161 217. Wang P-X, Deng X-R, Zhang C-H, Yuan H-J. Gut microbiota and metabolic syndrome. Chin Med J (Engl). 2020;133(7):808-16.

1162 218. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1241214.

1163 219. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JL. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proceedings of the National Academy of Sciences. 2007;104(3):979-84.

1164 220. Armougom F, Henry M, Vialettes B, Raccach D, Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One. 2009;4(9):e7125.

1165 221. Koliada A, Syzenko G, Moseiko V, Budovska L, Puchkov K, Perederiy V, et al. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC microbiology. 2017;17(1):120-.

1166 222. Kong LC, Tap J, Aron-Wisnewsky J, Pelloux V, Basdevant A, Bouillot JL, et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr. 2013;98(1):16-24.

1167 223. Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux CW, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut. 2011;60(9):1214-23.

1168 224. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55-60.

1169 225. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proceedings of the National Academy of Sciences. 2008;105(43):16767-72.

1170 226. Lin HV, Frassetto A, Kowalik EJ, Jr., Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. Plos one. 2012;7(4):e35240.

1171 227. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091-103.

1172 228. Chakaroun RM, Massier L, Kovacs P. Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in Metabolic Disease: Perpetrators or Bystanders? Nutrients. 2020;12(4).

1173 229. Raso GM, Simeoli R, Iacono A, Santoro A, Paciello O, et al. Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin resistance, and weight loss in high-fat-fed mice. J Nutr Biochem. 2013;24(1):81-8.

1174 230. Martinez-Medina M, Denizot J, Drexu N, Robin F, Billard E, Bonnet R, et al. Western diet induces dysbiosis with increased <em>E</em> coli</em> /<em> in CEABAC10 mice</em> in CEABAC10 mice<em>,</em></em> alters host barrier function favouring AEC colonisation. Gut. 2014;63(1):116-24.

1175 231. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenhoch C, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014;514(7521):237-41.

1176 232. Burcelin R. Gut microbiota and immune crosstalk in metabolic disease. Molecular Metabolism. 2016;5(9):771-81.

1177 233. Su GL, Ko CW, Bercik P, Falck-Ytter Y, Sultan S, Weizman AV, et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159(2):697-705.

1178 234. Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018;67(11):1920-41.

1179 235. Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019;16(10):605-16.
236. Segal JP, Mullish BH, Quraishi MN, Iqbal T, Marchesi JR, Sokol H. Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. Therapeutic advances in gastroenterology. 2020;13:1756284820946904.

237. Yan F, Polk DB. Probiotics and Probiotic-Derived Functional Factors-Mechanistic Insights Into Applications for Intestinal Homeostasis. Frontiers in immunology. 2020;11:1428.

238. Mujagic Z, de Vos P, Boekschoten MV, Gover C, Pieters HH, de Wit NJ, et al. The effects of Lactobacillus plantarum on small intestinal barrier function and mucosal gene transcription; a randomized double-blind placebo controlled trial. Sci Rep. 2017;7:40128.

239. Schiavi E, Gleinscher M, Molloy E, Groeger D, Frei R, Festerl R, et al. The Surface-Associated Exopolysaccharide of Bifidobacterium longum 35624 Plays an Essential Role in Dampening Host Proinflammatory Responses and Repressing Local TH17 Responses. Appl Environ Microbiol. 2016;82(24):7185-96.

240. Alessandri G, Ossiprandi MC, MacSharry J, van Sinderen D, Ventura M. Bifidobacterial Dialogue With Its Human Host and Consequent Modulation of the Immune System. Frontiers in Immunology. 2019;10(2348).

241. Chelakkot C, Choi Y, Kim DK, Park HT, Ghim J, Kwon Y, et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp Mol Med. 2018;50(2):e450.

242. Bäuerl C, Coll-Marqués JM, Tarazona-González C, Pérez-Martínez G. Lactobacillus casei extracellular vesicles stimulate EGFR pathway likely due to the presence of proteins P40 and P75 bound to their surface. Scientific Reports. 2020;10(1):19237.

243. Hols P, Ledesma-García L, Gabant P, Mignot J. Mobilization of Microbiota Commensals and Their Bacteriocins for Therapeutics. Trends Microbiol. 2019;27(8):690-702.

244. Rivière A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. Frontiers in microbiology. 2016;7:979.

245. Parker EA, Roy T, D’Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition. 2018;45:125-34.e11.

246. Limketkai BN, Akobeng AK, Gordon M, Adepoju AA. Probiotics for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2020;7(7):Cd006634.

247. Kaur L, Gordon M, Baines PA, Iheozor-Ejiofor Z, Sinopoulou V, Akobeng AK. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;3(3):Cd005573.

248. Iheozor-Ejiofor Z, Kaur L, Gordon M, Baines PA, Sinopoulou V, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. The Cochrane database of systematic reviews. 2020;3(3):Cd007443-CD.

249. Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of probiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044-60.

250. Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12(12):Cd006095.

251. Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One. 2018;13(12):e0209205.

252. Ansari JM, Colasacco C, Emmanouil E, Kohlhepp S, Harriott O. Strain-level diversity of commercial probiotic isolates of Bacillus, Lactobacillus, and Saccharomyces species illustrated by molecular identification and phenotypic profiling. PloS one. 2019;14(3):e0213841-e.

253. Magnúsdóttir S, Heinken A, Kutt L, Ravcheev DA, Bauer E, Noronha A, et al. Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota. Nat Biotechnol. 2017;35(1):81-9.

254. Poyet M, Groussin M, Gibbons SM, Avila-Pacheco J, Jiang X, Kearney SM, et al. A library of human gut bacterial isolates paired with longitudinal multomics data enables mechanistic microbiome research. Nat Med. 2019;25(9):1442-52.

255. Devika NT, Raman K. Deciphering the metabolic capabilities of Bifidobacteria using genome-scale metabolic models. Scientific Reports. 2019;9(1):18222.

256. Yadav M, Shukla P. Recent systems biology approaches for probiotics use in health aspects: a review. 3 Biotech. 2019;9(12):448-

257. Tabashsum Z, Peng M, Salaheen S, Comis C, Debabrata B. Competitive elimination and virulence property alteration of Campylobacter jejuni by genetically engineered Lactobacillus casei. Food Control. 2017;85.

258. Schellenberger J, Que R, Fleming RMT, Thiele I, Orth JD, Feist AM, et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0. Nature Protocols. 2011;6(9):1290-307.

259. Ottman N, Davids M, Suarez-Diez M, Boeren S, Schaap PJ, Martins Dos Santos VAP, et al. Genome-Scale Model and Omics Analysis of Metabolic Capacities of Akkermansia muciniphila Reveal a Preferential Mucus- Degrading Lifestyle. Appl Environ Microbiol. 2017;83(18).
281. Gomollón F, Dignass A, Annesi V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3-25.

282. Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(3):240-8.

283. Allegretti JR, Kassam Z, Mullish BH, Chiang A, Carrellas M, Hurtado J, et al. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clin Gastroenterol Hepatol. 2020;18(4):855-63.e2.

284. Kootte RS, Levin E, Salojarvi J, Smits LP, Hartstra AV, Udayappan SD, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017;26(4):611-9.e6.

285. Bajaj JS, Salzman NH, Acharya C, Sterling RK, White MB, Gavis EA, et al. Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. Hepatology. 2019;70(5):1690-703.

286. de Groot P, Nikolic T, Pellegrini S, Sordi V, Imangaliyev S, Rampanelli E, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. Gut. 2021;70(1):92-105.

287. Vendrik KEW, Ooijevaar RE, de Jong PRC, Laman JD, van Oosten BW, van Hilten JJ, et al. Fecal Microbiota Transplantation in Neurological Disorders. Front Cell Infect Microbiol. 2020;10:98.

288. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6246):1084-9.

289. Vékitou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6246):1079-84.

290. Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal microbiota transplantation overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595-602.

291. Barr JJ, Auro R, Furlan M, Whiteson KL, Erb ML, Pogliano J, et al. Bacteriophage adhering to mucus provide a non–host-derived immunity. Proceedings of the National Academy of Sciences. 2013;110(26):10771-6.

292. Zuo T, Wong SH, Lam K, Lui R, Cheung K, Tang W, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut. 2018;67(4):634-43.

293. Zuo T, Wong SH, Cheung CP, Lam K, Lui R, Cheung K, et al. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nat Commun. 2018;9(1):3663.

294. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bhatti R, Grasis JA, et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology. 2017;152(4):799-811.e7.

295. Mabwi HA, Kim E, Song D-G, Yoon HS, Pan C-H, Komba EVG, et al. Synthetic gut microbiome: Advances and challenges. Computational and Structural Biotechnology Journal. 2021;19:363-71.

296. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, et al. Stool substitute transplantation therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome. 2013;1(1):3.

297. Rode AA, Chehri M, Krogsgaard LR, Heno KK, Svensden AT, Ribberholt I, et al. Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridiodes difficile infections. Alimentary Pharmacol & Therapeutics. n/a(n/a).

298. Staley C, Hamilton MJ, Vaughn BP, Graiziger CT, Newman KM, Kabage AJ, et al. Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study. Am J Gastroenterol. 2017;112(6):940-7.
